SCHEMBL5451259

SCHEMBL5451259

CCOc1ccc2c(C(N)=O)c(NC(=O)Nc3ccc(Br)cc3)sc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.47
RAB9A P51151 5/20 0.47
MEN1 O00255 6/20 0.45
KMT2A Q03164 6/20 0.45
NPC1 O15118 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
POLB P06746 4/20 0.45
TDP1 Q9NUW8 2/20 0.45
USP2 O75604 1/20 0.45
PKM P14618 2/20 0.45
KDM4E B2RXH2 2/20 0.45
TP53 P04637 1/20 0.44
ALDH1A1 P00352 3/20 0.43
LMNA P02545 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
GAA P10253 2/20 0.42
HSD17B10 Q99714 1/20 0.41
MITF O75030 1/20 0.41
PAX8 Q06710 1/20 0.41
PPARG P37231 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460276 0.94 MAPT (0.51) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL5457894 0.91 MAPT (0.46) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL5448415 0.91 MAPT (0.50) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL5455798 0.90 MAPT (0.47) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL5460194 0.90 MAPT (0.57) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL5449712 0.88 MAPT (0.44) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL5455953 0.87 MEN1 (0.47) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL5456387 0.87 KMT2A (0.51) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL5453549 0.86 MEN1 (0.46) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL5453276 0.83 CSNK1D (0.46) MAPTRAB9AMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MAPT 21/4885RAB9A 948/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.